Questionnaire
BehavioralQuestionnaire completion
NCT Number: NCT06665802
The purpose of this study is to assess if adolescents affected with Avoidant and Restrictive Food Intake Disorders (ARFID) had more frequent precocious pediatric feeding disorders before 4 years old compared to healthy adolescents.
Looking for future studies?
Notify Me12 year–17 year
All sexes
Observational
Hôpital Cochin, Paris, France
This research focuses on retrospective analysis of early pediatric feeding disorders seen for ARFID in adolescence in two departments of the DMU MEFADO.
This assessment will be implemented during a hospital visit by a questionnaire completed by the patient's parents covering the first years of the child's life in medical, behavioural and dietary terms. This questionnaire was created for this study and, therefore, is not validated for general population. The parents will also complete the Montreal Children Feeding scale based on their memories.
The Montreal Children Feeding scale is a validated parental self-questionnaire, allowing the screening of feeding and eating disorders in children under 6 years old. Since the study specific questionnaire is not validated, 60 non-ARFID controls will be included in the study for questionnaires completion. The research also focuses on the psychopathological profile of these adolescents with ARFID regarding their degree of anxiety, their degree of depression, their possible autistic traits and their sensory sensitivity. These aspects will be studied by validated self- and hetero-questionnaires standardized for these fields. The emotional expression of the parents will be assessed during a brief qualitative interview type "Five-Minute Speech Sample".
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For all patients:
For ARFID patients:
For non-ARFID patients:
Exclusion criteria
For all patients:
For ARFID patients:
For non-ARFID patients:
Questionnaire completion
Time frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent FPD before the age of 4 years compared to adolescents without ARFID by using the Montreal scale score (61 or more) and/or the specific study questionnaire (at least 4 positive answers)
Time frame: 1 day
Evaluation of growth effects of ARFID by measuring the Z score and Tanner stage.
Time frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent hypersensoring or hyposensoring traits compared to adolescents without ARFID by using Sensoring Processing Scale Inventory (SPSI)
Time frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent anxiety compared to adolescents without ARFID by using the GAD-7 scale (score of 5 or more)
Time frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent depression compared to adolescents without ARFID by using the ADRS (Adolescent Depression Rating Sclale) (score of 4 or more)
Time frame: 1 day
Determine whether adolescents recently diagnosed with ARFID have more frequent autistic traits compared to adolescents without ARFID by using the Autism Spectrum Screening Questionnaire (ASSQ) (score of 13 or more)
Time frame: 1 day
Compare parent's emotional expression for adolescents recently diagnosed with ARFID to adolescents without ARFID by using the five minute speech sample.
Assistance Publique - Hôpitaux de Paris
Other
Acronym: ARFIDOS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06359951
Anxiety, Anxiety Disorders
Chicago, Illinois, United States
View Trial DetailsNCT05548699
Anxiety Disorders, Anxiety and Fear
Bad Mergentheim, Baden-Wurttemberg, Germany
View Trial DetailsNCT05738967
Anxiety, Anxiety Disorders
Houston, Texas, United States
View Trial DetailsNCT06013137
Anxiety, Anxiety Disorders
Lebanon, New Hampshire, United States
View Trial Details